RTX-224, an Allogeneic Red Cell Therapeutic Expressing IL-12 and 4-1BBL, Exhibits Potent In Vitro and In Vivo Activity and a Favorable Safety Profile

Anne-Sophie Dugast, Enping Hong, Maegan Hoover, Arjun Bollampalli, Douglas C. McLaughlin, Omkar Bhate, Timothy J. Lyford, Torben Straight Nissen, Christopher L. Carpenter, Thomas J. Wickham, Lori Melançon, and Sivan Elloul. Poster presented at the American Association for Cancer Research (AACR) annual meeting on April 2, 2019, Atlanta, GA